Table 1.

Comparison of immunohistochemical variables among familial breast tumors with amplification at 8q21-23 and/or 17q22-25, amplification at 13q21-31, and without amplifications

Cases with amp8q21-23 and/or amp17q22-25
P*Cases with amp13q21-31
PNonamplifier cases
P
n (%)n (%)n (%)
Grade
    12 (9.1)NS1 (11.1)NS13 (37.1)0.028
    26 (27.3)4 (44.4)9 (25.7)
    314 (63.6)4 (44.4)13 (37.1)
Mitosis
    13 (15.0)NS4 (44.4)NS20 (55.6)0.006
    24 (20.0)1 (11.1)4 (11.1)
    313 (65.0)4 (44.4)12 (33.3)
Ki-67
    0-5%7 (30.4)NS5 (62.5)NS24 (64.9)0.040
    6-25%9 (39.1)2 (25.0)7 (18.9)
    >25%7 (30.4)1 (12.5)6 (16.2)
Estrogen receptor
    Negative11 (47.8)0.0280NS (0.085)14 (36.8)NS
    Positive12 (52.2)8 (100)24 (63.2)
Progesterone receptor
    Negative14 (60.9)0.0371 (12.5)NS (0.115)18 (47.4)NS
    Positive9 (39.1)7 (87.5)20 (52.6)
p53
    Negative16 (69.6)NS7 (87.5)NS28 (75.7)NS
    Positive7 (30.4)1 (12.5)9 (24.3)
p120ctn
    Negative15 (78.9)NS8 (100)0.01316 (50.0)0.023
    Positive4 (21.1)016 (50.0)
E-Cadherin
    Negative12 (60.0)NS3 (37.5)NS12 (36.4)0.047
    Positive8 (40.0)5 (62.5)21 (63.6)
P-Cadherin
    Negative16 (80.0)NS8 (100)NS26 (81.3)NS
    Positive4 (20.0)06 (18.8)
γ-Catenin
    Negative13 (72.2)NS6 (75.0)NS25 (78.1)NS
    Positive5 (27.8)2 (25.0)7 (21.9)
Bcl-2
    Negative14 (63.6)NS5 (62.5)NS22 (59.5)NS
    Positive8 (36.4)3 (37.5)15 (40.5)
  • NOTE: All P values were obtained by the χ2 contingency test using Fisher's exact test correction when necessary. P < 0.05 was considered significant. NS, nonsignificant differences.

  • * P obtained by comparison of cases with amp8q/17q versus amp13q.

  • P obtained by comparison of cases with amp13q versus nonamplifier tumors.

  • P obtained by comparison of cases with amp8q/17q versus nonamplifier tumors.